Several clinical trials of immune checkpoint inhibitors (anti-PD-1, PD-L1, and CTLA-4 Abs) administered as monotherapy or in combination with other agents or modalities are ongoing (Table 1) and may provide further treatment options for patients with advanced MCC in the near future. The gene discussed is CTLA4; the disease is Merkel cell skin cancer.